Literature DB >> 10093056

Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats.

H A Baba1, T Iwai, M Bauer, M Irlbeck, K W Schmid, H G Zimmer.   

Abstract

The effects of the angiotensin II receptor type 1 (AT1) antagonist losartan on pressure overload-induced left ventricular (LV) hypertrophy were studied in female Sprague-Dawley rats. Starting on the day of surgery, losartan (L, 12 mg/kg/day) was administered as continuous intraperitoneal infusion for 2 weeks by using alzet mini-osmotic-pumps (model 2002). This dose of losartan shifted the in vivo dose-response curve of the angiotensin II-induced elevation of left ventricular systolic pressure (LVSP) to the right. Pressure overload was achieved by placing a band around the aortic arch. This caused an aortic stenosis (AS) with an outer diameter of 1.0 mm. The hemodynamic effects were measured in the intact, anesthetized rats (n = 15). The hearts were excised, and the weights of the left (LV) and right ventricle (RV) were determined. Some of these hearts (n = 7) were perfused with collagenase to obtain isolated cardiac myocytes for the measurement of cell volume. Other hearts (n = 8) were examined for morphological changes. In the animals with AS, LVSP was markedly elevated. Furthermore, LV weight and LV myocyte cell volume were increased in this group, while RV weight and RV myocyte cell volume remained stable in all the groups. L had no significant effect on the AS-induced increase in LVSP and cell size parameters, nor on the weight gain of the LV. Histological analysis revealed that the AS-induced enlargement of the mean myocyte diameter was not affected by L. The interstitial collagen fraction was increased in the AS rats and became normalized by L. These data suggest that the renin-angiotensin system might not be involved in the development of pressure-induced cardiac hypertrophy within the time-frame of these experiments, but that it does play a major role in the genesis of the interstitial fibrosis which is a typical feature of this pathophysiological condition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10093056     DOI: 10.1006/jmcc.1998.0879

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

1.  Role of the angiotensin II receptor blocker valsartan in heart failure.

Authors:  R L Webb; M de Gasparo
Journal:  Exp Clin Cardiol       Date:  2001

Review 2.  The Extracellular Matrix in Ischemic and Nonischemic Heart Failure.

Authors:  Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2019-06-20       Impact factor: 17.367

3.  Losartan reduces mortality in a genetic model of heart failure.

Authors:  Sophie Günther; Hideo A Baba; Steffen Hauptmann; Hans-Jürgen Holzhausen; Claudia Grossmann; Karla Punkt; Tina Kusche; Larry R Jones; Ulrich Gergs; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-10       Impact factor: 3.000

Review 4.  Role of microangiopathy in diabetic cardiomyopathy.

Authors:  Adriana Adameova; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

5.  The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat hearts.

Authors:  Barbara Ziegelhöffer-Mihalovicová; Wilfried Briest; Hideo A Baba; Beate Rassler; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

6.  Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.

Authors:  Nicole Brüchert; Nirmala Mavila; Peter Boknik; Hideo A Baba; Larissa Fabritz; Ulrich Gergs; Uwe Kirchhefer; Paulus Kirchhof; Marek Matus; Wilhelm Schmitz; Anna A DePaoli-Roach; Joachim Neumann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

7.  Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.

Authors:  Kenichi Watanabe; Rajarajan A Thandavarayan; Meilei Harima; Flori R Sari; Narasimman Gurusamy; Punniyakoti T Veeraveedu; Sayaka Mito; Wawaimuli Arozal; Vijayakumar Sukumaran; Arun Prasath Laksmanan; Vivian Soetikno; Makoto Kodama; Yoshifusa Aizawa
Journal:  Curr Cardiol Rev       Date:  2010-11

8.  Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade.

Authors:  Kalkidan Bishu; Ozgur Ogut; Sudhir Kushwaha; Selma F Mohammed; Tomohito Ohtani; Xiaolei Xu; Frank V Brozovich; Margaret M Redfield
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

9.  Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats.

Authors:  Jia Hao; Chan-Hyung Kim; Tae-Sun Ha; Hee-Yul Ahn
Journal:  J Vet Sci       Date:  2007-06       Impact factor: 1.672

Review 10.  Scanning ion conductance microscopy: a convergent high-resolution technology for multi-parametric analysis of living cardiovascular cells.

Authors:  Michele Miragoli; Alexey Moshkov; Pavel Novak; Andrew Shevchuk; Viacheslav O Nikolaev; Ismail El-Hamamsy; Claire M F Potter; Peter Wright; S H Sheikh Abdul Kadir; Alexander R Lyon; Jane A Mitchell; Adrian H Chester; David Klenerman; Max J Lab; Yuri E Korchev; Sian E Harding; Julia Gorelik
Journal:  J R Soc Interface       Date:  2011-02-16       Impact factor: 4.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.